Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination. by Funk, Sebastian et al.
LSHTM Research Online
Funk, Sebastian; Knapp, Jennifer K; Lebo, Emmaculate; Reef, Susan E; Dabbagh, Alya J; Kretsinger,
Katrina; Jit, Mark; Edmunds, W John; Strebel, Peter M; (2019) Combining serological and con-
tact data to derive target immunity levels for achieving and maintaining measles elimination. BMC
medicine, 17 (1). p. 180. ISSN 1741-7015 DOI: https://doi.org/10.1186/s12916-019-1413-7
Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4654607/
DOI: https://doi.org/10.1186/s12916-019-1413-7
Usage Guidelines:
Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively
contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
https://researchonline.lshtm.ac.uk
Funk et al. BMCMedicine          (2019) 17:180 
https://doi.org/10.1186/s12916-019-1413-7
RESEARCH ARTICLE Open Access
Combining serological and contact data
to derive target immunity levels for achieving
and maintaining measles elimination
Sebastian Funk1,2* , Jennifer K. Knapp3, Emmaculate Lebo3, Susan E. Reef3, Alya J. Dabbagh4,
Katrina Kretsinger4, Mark Jit1,2,6,7, W. John Edmunds1,2 and Peter M. Strebel5
Abstract
Background: Vaccination has reduced the global incidence of measles to the lowest rates in history. However, local
interruption of measles virus transmission requires sustained high levels of population immunity that can be
challenging to achieve and maintain. The herd immunity threshold for measles is typically stipulated at 90–95%. This
figure does not easily translate into age-specific immunity levels required to interrupt transmission. Previous estimates
of such levels were based on speculative contact patterns based on historical data from high-income countries. The
aim of this study was to determine age-specific immunity levels that would ensure elimination of measles when
taking into account empirically observed contact patterns.
Methods: We combined estimated immunity levels from serological data in 17 countries with studies of age-specific
mixing patterns to derive contact-adjusted immunity levels. We then compared these to case data from the 10 years
following the seroprevalence studies to establish a contact-adjusted immunity threshold for elimination. We lastly
combined a range of hypothetical immunity profiles with contact data from a wide range of socioeconomic and
demographic settings to determine whether they would be sufficient for elimination.
Results: We found that contact-adjusted immunity levels were able to predict whether countries would experience
outbreaks in the decade following the serological studies in about 70% of countries. The corresponding threshold
level of contact-adjusted immunity was found to be 93%, corresponding to an average basic reproduction number of
approximately 14. Testing different scenarios of immunity with this threshold level using contact studies from around
the world, we found that 95% immunity would have to be achieved by the age of five and maintained across older
age groups to guarantee elimination. This reflects a greater level of immunity required in 5–9-year-olds than
established previously.
Conclusions: The immunity levels we found necessary for measles elimination are higher than previous guidance.
The importance of achieving high immunity levels in 5–9-year-olds presents both a challenge and an opportunity.
While such high levels can be difficult to achieve, school entry provides an opportunity to ensure sufficient
vaccination coverage. Combined with observations of contact patterns, further national and sub-national serological
studies could serve to highlight key gaps in immunity that need to be filled in order to achieve national and regional
measles elimination.
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Background
Measles, a highly contagious immunising infection, could
be a future target for eradication [1, 2]. Since the intro-
duction of vaccination in the early 1960s, mortality and
morbidity from measles has declined drastically [3]. Nev-
ertheless, outbreaks continue to occur, and achieving
regional elimination, or interruption of transmission, has
been challenging [4].
Control of measles is achieved through vaccination in
early childhood, and the vaccine is part of routine immu-
nisation schedules worldwide. In principle, a functioning
health system would aim to vaccinate every child. In prac-
tice, 100% coverage with all recommended doses is never
achieved. Moreover, not every administration of a vac-
cine confers immunity, and protection from a vaccine can
wane over time. However, even if not everyone in a popu-
lation is immune, the indirect protection provided by the
presence of immune individuals can be sufficient to pre-
vent outbreaks [5]. For measles, it has been shown that
in a randomly mixing population, the level of immunity
required to achieve this so-called “herd immunity” is in
the order of 90–95% [6].
Knowledge of the level of immunity required in a pop-
ulation to achieve herd immunity can be used to set
national vaccination targets. However, even if current lev-
els of vaccination are high enough to achieve the level of
immunisation required for herd immunity in new birth
cohorts, outbreaks can occur if there are immunity gaps
in older age groups. To assess the ability of a country or
region to achieve andmaintain elimination, that is the sus-
tained absence of endemic transmission, immunity levels
must therefore be considered across all age groups. These
levels are affected by historical and current routine vac-
cination coverage, but also by vaccination campaigns and
past outbreaks that conferred natural immunity.
For this reason, in the late 1990s, the World Health
Organization (WHO) European Region (EURO) derived
age-specific target immunity profiles, or the levels of
immunity necessary in different age groups in order to
achieve elimination [7]. These profiles are widely applied
within and occasionally outside Europe to assess progress
towards elimination [8–16]. Based on a basic reproduc-
tion number (or number of secondary cases produced by
a typical infective in a totally susceptible population) of
11, it was recommended to ensure that at least 85% of
1–4-year-olds, 90% of 5–9-year-olds and 95% of 10-year-
olds and older possess immunity against measles [17].
Unlike vaccination coverage targets, immunity targets
reflect the effect of susceptibility in all age groups and
highlight the potential need for campaigns to close any
gaps in immunity.
The aforementioned target immunity levels derived
in the late 1990s were based on assumed age-specific
contact patterns matched to the pre-vaccination measles
epidemiology in England and Wales. Since then, much
work has gone into better quantifying the amount of
transmission-relevant contact occurring between differ-
ent age groups. Diary-based studies have been conducted
across Europe [18, 19], as well as in Vietnam [20], China
[21], Uganda [22], Zimbabwe [23] and elsewhere. While
other methods for measuring social contact patterns exist
[24–26], contact data from diary studies have become
the de facto standard for studying age-specific infectious
disease dynamics. Mathematical models of transmission
based on these observed patterns have consistently out-
performed those based on homogeneous mixing [27–29].
Here, we aimed to evaluate current guidelines on target
immunity levels for measles taking into account contact
patterns observed in diary studies. To this end, we com-
bined the observed age-specific social mixing patterns
with observed or hypothesised immunity levels to calcu-
late contact-adjusted immunity, akin to the mean level of
immunity across the population but taking into account
that some age groups have more contact with each other
than others. We validated this method by testing the
extent to which contact-adjusted immunity levels based
on nationwide serological studies conducted in different
countries in the late 1990s and early 2000s could have been
used to predict the case load in the following decade. We
then calculated contact-adjusted immunity levels from
a range of hypothetical scenarios of age-specific immu-
nity, including previous recommended immunity levels.
We assessed whether these levels would be sufficient for
achieving and maintaining elimination.
Methods
Predicting elimination from seroprevalence data
We estimated population-level immunity levels from sero-
prevalence data using the different model variants out-
lined below and compared them to the number of cases
experienced over 10 years using Spearman’s rank correla-
tion coefficient.
We further tested different thresholds for these levels to
classify countries as being at risk of outbreaks or not. We
calculated the misclassification error (MCE) as the pro-
portion of countries that were incorrectly classified based
on the given immunity threshold level and a threshold of
the number of cases experienced in the 10 years following
the seroprevalence study.
Immunity model: contact-adjusted vs. plain
We assumed that the force of infection λi experienced by
age group i only depends on the rate of contact with the
same and other age groups and the prevalence of infection
in the respective age groups:
λi =
∑
j
λij =
∑
j
βij
Ij
Nj
(1)
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where λij is the force of infection exerted by age group j
on age group i, βij is the infection rate, or the rate at which
individuals in age group i contact individuals out of a total
number Nj in age group j and become infected if these are
infectious, and Ij is the number of infectious people in age
group j. This formulation of the force of infection assumes
that the rate of infection between two random individu-
als depends on their ages only and that the probability of
a given contacted member of age group j to be with some-
one infectious depends on population-level prevalence of
infection only.
We further write the infection rate βij as:
βij = pInfφij (2)
where pInf is the probability that a contact between a
susceptible and infectious person leads to infection, here
assumed age-independent, and φij is the number of con-
tacts an individual of age group j makes with those of age
group i per unit time.
The basic reproduction number R0 is defined as the
mean number of new cases generated by a single infec-
tious individual in a completely susceptible population. In
a systemwith multiple host types (here: age groups), it can
be calculated as the spectral radius (or largest eigenvalue)
of the next-generation matrix (NGM) K [30]:
R0 = ρ(K) (3)
The elements of the next-generation matrix K can be
written as:
kij = qφij NiNj (4)
where q is a scale factor that, assuming that infectious-
ness stays constant while a person is infectious, is the
probability of infection upon contact pInf multiplied with
the duration of infectiousness DInf. If a proportion ri of
age group i is immune, this changes the initially suscep-
tible population from Ni to Ni(1 − ri). The reproduction
number for an invading infection in such a population is:
R = ρ(K′) (5)
where, again, ρ denotes the spectral radius and K′ is a
matrix with elements:
k′ij = qφij
Ni(1 − ri)
Nj
. (6)
In classical mathematical epidemiology in a well-
mixed population, the relationship between the basic
reproduction number R0 and the effective reproduction
number R is:
R = (1 − r)R0 (7)
where r is the proportion of the population that is
immune. We interpret:
r′ = (1 − R/R0) =
(
1 − ρ(K
′)
ρ(K)
)
(8)
as contact-adjusted immunity, that is the equivalent of
population immunity once age-specific contact patterns
are taken into account. Note that q cancels out, so that
calculation of contact-adjusted immunity only requires
the contact matrix φij, population sizes Ni and immunity
levels ri.
An assumption of homogeneous mixing is equivalent to
assuming that φij = δnj, that is the rate of contact of group
i being with group j depends only on an overall level of
contact δ and the proportion nj = Nj/N of the population
that are in group j,N = ∑Nj being the overall population
size. This, in turn, means that the infection rate is βij =
δpinfnj and the force of infection (Eq. 1) is independent of
age group:
λi = δpinf IN (9)
This is equal to the force of infection in a standard SIR
model with infection rate β if we set β = δpinf, that is the
infection rate is equal to the rate of contact times the prob-
ability of infection upon contact between a susceptible
and infectious individual.
In that case, the NGM of Eq. (4) reduces to:
kij = qniδ (10)
with q = pInfDInf. This matrix has rank 1 (as all rows are
equal), and its only non-zero eigenvalue is given by the
trace:
R0 = qδ = βDInf (11)
If the proportion immune of those in age group i is ri, the
elements of K′ are:
k′ij = q(1 − ri)niδ (12)
and
R = βDInf
∑
i
(1 − ri)ni = rR0 (13)
where r is the proportion of the population that is
immune. We call this factor r plain immunity.
R0 model: fixed vs. scaled
Elimination is equivalent to a situation where R < 1 in
Eq. 5. For a given basic reproduction number R0, this cor-
responds to contact adjusted immunity r being greater
than a threshold level r∗ in Eq. 8.
The value of the basic reproduction number R0 would
be expected to vary between settings, and this could be
reflected in different values across countries [31]. Differ-
ences in contact patterns (due to factors such as cultural
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difference, schooling, population density or demography)
would be expected to underlie such differences. It is
unclear, though, whether these differences are measur-
able in diary studies, or whether it is masked by inherent
uncertainty in these observations, as well as differences in
study design and data collection. We therefore tested two
interpretations of the contact matrices estimated by diary
studies in order to establish this threshold.
Under the first, more conservative interpretation (fixed
R0), the contact matrices were taken to capture differences
in contact rates between age groups, but not differences
between overall levels of contact between the countries.
This is equivalent to setting R0 to be equal across coun-
tries while still allowing difference in the relative contact
rates between age groups. In this case, we would expect a
single threshold level of contact-adjusted immunity given
by r∗ = 1 − 1/R0.
Under the second interpretation (scaled R0), we
assumed R0 to scale according to the observed contact
patterns in each country. In this case, every country would
be expected to have a different threshold of contact-
adjusted immunity depending on its value of R0, reflecting
the average basic reproduction number within the coun-
try. We calculated a scaling factor c for each country such
that the basic reproduction number in the country was
given by:
R0 = cR0 (14)
where R0 is the mean basic reproduction number across
countries. The factor c can be calculated as the spectral
radius of a given contact matrix divided by the mean of
the spectral radii across countries. Instead of working with
different values of the basic reproduction number R0, we
rescaled contacted-adjusted immunity in each country as:
r′ = 1 − (1 − r)c (15)
With this formulation, we would again expect a single
threshold of scaled contact-adjusted immunity given by
r′∗ = 1 − 1/R0.
Vaccination model: projected vs. ignored
Seroprevalence studies only provide a single, cross-
sectional snapshot of immunity in a population. Follow-
ing such a study, vaccination uptake, natural immunity
and ageing combine to change the age-specific immu-
nity levels. We compared a model where vaccination was
ignored and the measured seroprevalence taken as fixed
over the 10-year time period to one where we used an
average of projected immunity levels, which were updated
using information on vaccination uptake in the years fol-
lowing the seroprevalence study. In principle, updating
immunity levels with measured vaccination coverage and
wild-type measles circulation should improve estimates
of population-level immunity. In practice, this relies on
accurate measurements of both vaccination coverage and
case numbers as well as modelling decisions on assumed
vaccine efficacy, maternal immunity and distribution of
multiple doses (e.g. randomly vs. preferentially to children
that have already received a dose), which could mask any
gains made from having up-to-date immunity estimates.
Here, we focused on added immunity due to vaccination
and assumed that the added immunity due to wild-type
measles circulation was negligible. Serological samples
from under-1-year-olds were only available from 7 of the
17 countries in the ESEN2 study, and the number of sam-
ples from each country is too small to produce good
estimates (676 samples in total); we combined all these
samples to produce an overall estimate of maternal immu-
nity of approximately 40% amongst under-1-year-olds.We
assumed that immunity in the age group that contained
the scheduled age of the first dose of measles was given
by a country-specific scaling factor multiplied with the
reported coverage in that year. This factor would reflect
the proportion of children in that age group immunised
at any point in time, as a fraction of the ones immu-
nised by the time of departure from the age group. The
factor was estimated by comparing the observed sero-
prevalence with the level of coverage reported in that year.
For any subsequent doses, we assumed that the vaccine
was preferentially given to those that had received a pre-
vious dose or doses of the vaccine, as could be estimated
from the reported coverage at the time children in that
cohort would have been eligible for the previous dose(s).
We assumed a vaccine efficacy per dose of 95% [32].
Contact matrices
We established contact matrices from diary studies con-
ducted in a range of different settings using a bootstrap,
randomly sampling P individuals with replacement from
the P participants of a contact survey. We then deter-
mined a weighted average dij of the number of contacts
in different age groups j made by participants of each age
group i, giving weekday contacts 5/2 times the weight of
weekend contacts. We further obtained symmetric matri-
ces, i.e. ones fulfilling cijni = cjinj by rescaling:
cij = 12
1
ni
(
dijni + djinj
)
(16)
This gave the elements of the contact matrix φij = cij/T ,
scaled by the time period T over which contacts were
measured (usually 24 h).
Data sources
We considered the annual number of measles cases
reported by each country to WHO. We used serolog-
ical studies conducted in 17 countries of the WHO
EURO as part of the European Sero-Epidemiology Net-
work 2 (ESEN2) project to determine immunity levels
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at the times of the studies [10]. Equivocal samples were
interpreted as positive as in the original study, but we
also tested scenarios where they were removed from the
sample or interpreted as negative. We took into account
uncertainty by drawing from the individual samples using
a bootstrap (n = 1000) and using the re-sampled immu-
nity levels with re-sampled contact matrices to estimate
contact-adjusted immunity. We ensured visually that the
number of bootstrap samples chosen produced stable
mean estimates of contact-adjusted immunity levels (see
Additional file 1: Figure S1). Since contact studies were
not available for all countries in ESEN2, contact studies
from representative countries were used where necessary
(for mediterranean countries, Italy; for Eastern European
countries, Poland; for Sweden, Finland; for Ireland, Great
Britain).
We used diary studies available on the Zenodo
Social Contact Data Repository (https://zenodo.org/
communities/social_contact_data), to determine contact
matrices for 17 countries and the Hong Kong Special
Administrative Region of China [33–37], a study con-
ducted in Uganda [22] and a further study conducted in
five countries of South East Asia.
Computation
All computations were done with the R statistical com-
puting language [38]. Contact matrices were calculated
using the contact_matrix function in the socialmixr pack-
age [39], and contact-adjusted immunity calculated using
the adjust_immunity function in the epimixr package [40].
Results
Contact-adjusted immunity levels from serological studies
We first tested the ability of nationwide seroprevalence
studies to predict the cases in the decade following,
using different definitions of population-level immunity.
Overall, the 17 countries that took part in the ESEN2
study in the early 2000s reported 59,494 measles cases
to WHO in the 10 years following the study. The num-
ber of cases experienced by individual countries varied
widely (Fig. 1 and Table 1). Slovakia, where measles was
declared eliminated in 1999, only reported a total of 2
cases (both in 2004) in these 10 years. Bulgaria, on the
other hand, reported over 20,000 cases, largely as part of a
large outbreak in 2009/10.
Comparing the immunity levels with the mean number
of annual measles cases in the 10-year period yielded the
expected negative correlation with most models (Table 2).
Contact-adjusted immunity levels estimated based on the
serological profiles were better correlated with the case
load than plain immunity levels. Further, interpreting
equivocal samples as positive yielded the best correla-
tion, but scaling R0 according to measured contacts did
not improve correlations compared to using a fixed R0.
Projecting national vaccination uptake in the years follow-
ing the serological surveys onto the observed immunity
levels yielded better correlations than just using the snap-
shots of seroprevalence. For the remaining analyses, we
therefore used a fixed R0, interpreted equivocal samples as
positive, and corrected immunity levels with vaccination
uptake. The resulting immunity levels for the 17 coun-
tries in the ESEN2 study are shown in the rightmost two
columns of Table 1.
The best model had correlation of − 0.53 (Spearman’s
rank correlation, 90% credible interval (CI) − 0.59–
(− 0.46)) for contact-adjusted immunity and − 0.29 (90%
CI − 0.36–(− 0.21)) for plain immunity. Notable
outliers in the correlation between immunity levels
and case load were Latvia (contact-adjusted immunity
71%, plain 82%, 16 cases over 10 years) in one direction
Fig. 1Maximum number of cases in a year out of the 10 years following the ESEN2 study, in cases per million inhabitants, on a logarithmic scale.
Numbers at the top of the bars are the total number of cases reported in the year with most cases. The dotted vertical line indicates the threshold
delineation between countries that did (right) or did not (left) experience large outbreaks when testing the ability of population-level immunity
metrics to predict either
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Table 1 Measles cases in the 10 years following the ESEN2 serological study, and mean estimated population
immunity (contact-adjusted or not, with fixed R0 and equivocal samples interpreted as positive) based on the study and adjusted for
vaccination uptake
Cases Immunity
Country Total (10 years) Maximum annual Mean annual (per million) Maximum annual (per million) Contact-adjusted Plain
Slovakia 2 2 0.037 0.37 0.96 0.96
Hungary 12 5 0.12 0.5 0.95 0.95
Czech Republic 84 30 0.82 2.9 0.98 0.98
Latvia 16 7 0.72 3.1 0.71 0.82
Sweden 210 62 2.4 7 0.94 0.94
Lithuania 58 35 1.7 10 0.91 0.93
Slovenia 26 22 1.3 11 0.96 0.96
Malta 14 6 3.5 15 0.93 0.95
Luxembourg 10 8 2.3 18 0.95 0.96
UK 6001 1445 10 25 0.92 0.96
Spain 3419 1842 8.6 46 0.95 0.98
Belgium 1066 576 10 56 0.85 0.94
Cyprus 111 90 11 87 0.84 0.93
Ireland 1687 443 40 105 0.88 0.91
Israel 1792 931 30 155 0.94 0.95
Romania 20570 7450 93 337 0.92 0.96
Bulgaria 24416 22004 305 2750 0.82 0.88
(low estimated immunity but no outbreaks), and
Spain (contact-adjusted immunity 95%, plain 98%,> 3000
cases) and Israel (contact-adjusted immunity 94%, plain
95%, > 1500 cases) in the other (high estimated immunity
but outbreaks).
To test the predictive ability of estimated seroprevalence
levels in combination with age-specific mixing, we split
the countries into those that experienced large outbreaks
in the 10 years following the serological studies and those
that did not. We set the threshold at an average of 5 per
million or, equivalently, a maximum annual cases of 20 per
million (see dashed line in Fig. 1). We then tested differ-
ent threshold immunity levels (ranging from 80% to 99%,
in increments of 1%) and classified countries as being at
risk of outbreaks or not based on whether their estimated
immunity levels fell below the threshold or not.
The threshold of contact-adjusted immunity yielding
best predictions was 93%, in which case about 70% of
countries were correctly classified (Fig. 2). With plain
immunity, this level is at 94%, and the corresponding
MCE is greater than with contact-adjusted immunity.
More generally, the behaviour of the MCE as a func-
tion of threshold level was more erratic when considering
plain instead of contact-adjusted immunity. In assessing
elimination prospects below, we used the threshold value
of 93%.
Scenarios
We investigated contact-adjusted immunity under pre-
viously recommended target immunity levels (85% in
under-5-year-olds, 90% in 5–9-year-olds and 95% in all
older age groups) in the settings for whichwe had access to
contact studies (17 countries and Hong Kong, Fig. 3a). We
used the identified threshold level of 93% as an indicator of
being at risk of outbreaks, implying that the mean R0 value
we found predictive of outbreaks in Europe was a good
estimate elsewhere. In this scenario, 5 out of 18 settings
had greater than 10% probability of adjusted immunity
levels lower than the 93% level found to best identify coun-
tries at risk of outbreaks: Taiwan (probability 95%), The
Netherlands (90%), Peru (68%), Uganda (63%) and the
UK (40%).
With alternative scenarios, the reproduction numbers
changed (Fig. 3 (b–e)). Raising immunity in under-5-year-
olds by 5 to 90% would increase adjusted immunity levels
only slightly, with 4 out of the 5 countries (exception:
Uganda) at risk under current target immunity levels still
at greater than 20% risk. On the other hand, raising immu-
nity in 5-to-9-year-olds by 5 to 95%would sharply increase
contact-adjusted immunity. In this scenario, all countries
would have 5% or less probability of being at risk of out-
breaks, with 16 out of 18 at less than 1% risk (exceptions:
Hong Kong 5%, Netherlands 3%).
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Table 2 Spearman’s rank correlation between immunity estimated from nationwide serology and (if contact-adjusted) contact studies
on the one hand and the mean number of cases in the 10 years following the studies on the other
Immunity model R0 model Vaccination model Equivocal samples Correlation (90% CI)
Contact-adjusted Fixed Projected Negative − 0.28 (− 0.36, − 0.2)
Contact-adjusted Fixed Ignored Negative − 0.16 (− 0.27, − 0.042)
Contact-adjusted Fixed Projected Positive − 0.53 (− 0.59,− 0.46)
Contact-adjusted Fixed Ignored Positive − 0.39 (− 0.49, − 0.27)
Contact-adjusted Fixed Projected Removed − 0.5 (− 0.56, − 0.43)
Contact-adjusted Fixed Ignored Removed − 0.37 (− 0.47, − 0.24)
Contact-adjusted Scaled Projected Negative − 0.23 (− 0.35, − 0.13)
Contact-adjusted Scaled Ignored Negative − 0.078 (− 0.21, 0.059)
Contact-adjusted Scaled Projected Positive − 0.49 (− 0.55, − 0.44)
Contact-adjusted Scaled Ignored Positive − 0.38 (− 0.47, − 0.25)
Contact-adjusted Scaled Projected Removed − 0.47 (− 0.52, − 0.4)
Contact-adjusted Scaled Ignored Removed − 0.37 (− 0.45, − 0.22)
Plain Fixed Projected Negative − 0.025 (− 0.086, 0.025)
Plain Fixed Ignored Negative 0.0098 (− 0.047, 0.054)
Plain Fixed Projected Positive − 0.29 (− 0.36, − 0.21)
Plain Fixed Ignored Positive − 0.23 (− 0.3, − 0.16)
Plain Fixed Projected Removed − 0.26 (− 0.33, − 0.19)
Plain Fixed Ignored Removed − 0.21 (− 0.28, − 0.14)
Plain Scaled Projected Negative 0.032 (− 0.0098, 0.081)
Plain Scaled Ignored Negative 0.056 (0.015, 0.11)
Plain Scaled Projected Positive − 0.22 (− 0.28, − 0.14)
Plain Scaled Ignored Positive − 0.16 (− 0.23, − 0.1)
Plain Scaled Projected Removed − 0.19 (− 0.25, − 0.13)
Plain Scaled Ignored Removed − 0.14 (− 0.2, − 0.083)
The model with the greatest absolute correlation is highlighted in italics
Fig. 2Misclassification error (MCE) as a function of the threshold level of for contact-adjusted or plain immunity. Dots give the mean MCE at the
tested threshold levels, connected by a line to guide the eye. The grey shades indicate a standard deviation around the mean (uncertainty coming
from both the serological sample and from the contact sample)
Funk et al. BMCMedicine          (2019) 17:180 Page 8 of 12
Fig. 3 Contact-adjusted immunity in different theoretical scenarios, with age-specific mixing as measured in diary studies. Each column represents
one of the scenarios of age-specific immunity (top), with differences between the settings given by their different mixing patterns. Scenarios from
left to right: a Current target levels. b 5% higher immunity in under 5-year-olds. c 5% higher immunity in 5–9-year-olds. d 5% lower immunity in
10–14-year-olds. e 5% higher immunity in 5–9-year-olds and 5% lower immunity in 15–19-year-olds
In scenarios where immunity in 5-to-9-year-olds was
raised but a gap in immunity was introduced in older gen-
erations, contact-adjusted immunity dropped below the
threshold level of 93% in some settings. A scenario of
reduced immunity in 10-to-14-year-olds by 5 to 90%while
retaining higher immunity in younger age groups resulted
in elevated risks of outbreaks in 13 out of 18 countries.
A scenario of reduced immunity in 14-to-19-year-olds by
5 to 90% while retaining higher immunity in younger age
groups resulted in elevated risks of outbreaks in 11 out of
18 countries.
Discussion
Taking into account age-specific mixing patterns and
applying these to immunity levels observed across Europe,
we were better able to predict outbreaks than by con-
sidering immunity alone. Combined with previous evi-
dence that using observed age-specific mixing improves
the accuracy of mathematical models, this suggests
that there is a case for taking these into account
when interpreting the results of serological studies
[27–29].
A threshold of 93% contact-adjusted immunity was
found to best predict outbreaks in the subsequent decade,
with approximately 70% of countries correctly assessed
to either be facing large outbreaks or not. However, in
the absence of any more detailed information on setting-
specific basic reproduction numbers, such a threshold
will only ever be an approximation. On the other hand,
setting-specific parameters are difficult to establish, are
subject to method-specific biases and can span a wide
range of values [31, 41]. In principle, country-specific
reproduction numbers should depend on the frequency
and types of contact within the population and should
therefore be amenable to measurement in contact studies
such as the ones used here. Yet, scaling estimated suscepti-
bility levels with the relative number of contacts reported
in each study gave no improved results over the simpler
version not using such scaling. In other words, while there
probably are differences in R0 between countries, these
do not appear to be identifiable in contact studies. At the
same time, the contact studies do have value in giving dif-
ferent weights to different age groups when calculating
contact-adjusted immunity depending on their contact
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patterns. We therefore argue that while the achieved 70%
of accuracy in predicting outbreaks is far from perfect,
aiming to achieve 93% or greater contact-adjusted immu-
nity in a population is a pragmatic choice that can be
informed by measurable quantities, that is age-specific
immunity levels and mixing patterns.
Current guidelines on target immunity levels are based
on estimates derived almost 20 years ago, and were based
on assumed mixing patterns matched to pre-vaccination
data from England and Wales. We have used trans-
mission models in combination with recently observed
age-specific contact patterns from a variety of European
and some non-European settings to assess whether these
guidelines are sufficient for achieving measles elimina-
tion. We investigated a range of settings with different
demographic profiles and cultural contexts: from high-
income settings characterised by low birth rates and an
ageing population (e.g., Germany or the UK) to hav-
ing more (Vietnam) or less (Taiwan) recently under-
gone the demographic transition to low birth rates, or
characterised by a high birth rate and young popula-
tion (Uganda). With observed mixing patterns, several
settings were found to be at risk of outbreaks even if
they achieved previously recommended target immunity
levels, including ones with very different demographic
profiles. Achieving 95% immunity in 5-to-9-year-olds, on
the other hand, would reduce transmission sufficiently
to achieve elimination in all except the most extreme
scenarios.
The importance of immunity levels in 5-to-9-year-olds
presents both a challenge and an opportunity: Levels as
high as 95% in this age group can only be maintained
through high levels of two-dose immunisation prior to
school entry. At the same time, entering this age group
coincides with school entry, which involves a level of
organisation that provides the opportunity to both check
the immunisation status of children and offer additional
vaccinations if necessary. The experience of the Pan-
American Health Organization in eliminating measles
supports these findings. A key component to interrupt-
ing measles virus transmission were periodic ‘follow-up’
vaccination campaigns of pre-school children, timed at 4-
year intervals to ensure high immunisation by the time of
school entry [42, 43]. Studies in the USA, where measles
was eliminated in 2000, suggest that different mini-
mum vaccine coverage levels were required to prevent
measles virus transmission among different age groups
[44]. School-aged populations accounted for the majority
of measles cases between 1976 and 1988, and compul-
sory vaccination as part of school attendance laws played
an important role in reducing measles incidence on the
path to elimination [45]. Where there were less stringent
vaccination requirements at school entry, more cases of
measles were observed [46]. Analyses of pre-elimination
measles outbreaks in the USA indicated that transmis-
sion occurred among highly vaccinated school-aged pop-
ulations, suggesting that higher population immunity
levels were needed among school-aged children com-
pared to preschool-aged children [47]. It has been pro-
posed that minimum coverage levels as low as 80% at
the second birthday of children may be sufficient to
prevent transmission among preschool-aged children in
the USA if population immunity is at least 93% among
over-5-year-olds [48].
While our results stress the role of 5-to-9-year-olds,
they also highlight the importance of not having gaps in
immunity in older age groups. This is particularly impor-
tant close to elimination as a lower force of infection
pushes cases into older age groups [49]. Given the higher
rate of complications of measles when experienced at
older age, ensuring immunity among adults will be impor-
tant not only for interrupting transmission, but also to
prevent serious episodes of disease [50].
Our study has several limitations. The delineation of
countries into having experienced outbreaks or not is
somewhat arbitrary, if in agreement with a milestone
towards measles eradication established by the World
Health Assembly [51]. Furthermore, the applied thresh-
old of 93% was found to best distinguish between coun-
tries that experienced outbreaks and those that did not,
but similar performance would have been achieved with
thresholds of 92% and, to a slightly lesser extent, 94%.
These values correspond roughly to the commonly used
range of 12–18 for the basic reproduction number. Apply-
ing these thresholds would have had strong consequences
for the assessment of elimination prospects for different
immunity profiles, leading to higher (for a threshold of
94%) or lower (for a threshold of 92%) age-specific immu-
nity targets. Depending on the local situation with respect
to measles elimination, a country may therefore decide
to apply less or more stringent immunity thresholds.
Moreover, population immunity represents past levels of
vaccine coverage or natural infection which may not be
reflective of the future. For example, immunity may be
high just after a major outbreak but such outbreaks could
occur again if coverage is sub-optimal. In addition, pop-
ulation migration can change immunity levels in a way
that is not captured by vaccination coverage figures. An
important caveat is therefore that seeing immunity suf-
ficient to interrupt transmission does not guarantee that
elimination is maintained if current levels of coverage are
insufficient.
We assumed that immunity levels and contact patterns
alone are sufficient to predict the expected case load. In
reality, numerous co-factors such as sub-national hetero-
geneity or contact patterns that are not captured in age-
specific contact matrices (e.g. household and schooling
structures) could have influenced this relationship. In fact,
Funk et al. BMCMedicine          (2019) 17:180 Page 10 of 12
the contact-adjusted immunity levels we estimated from
serological studies did not always correctly predict where
outbreaks could be expected. On the one hand, Latvia did
not experience large numbers of cases in spite of low levels
of contact-adjusted immunity. It was among the smallest
in our group of countries for which we had serological
data available andmay have been at lower risk of imported
cases. Still, they would have been expected to have seen
more cases given the results of the serological studies in
2003 and 2004, respectively. Immunity levels were as low
as 76% among all age groups and 62% in 5- to 9-year-olds
in 2003, but only 16 cases of measles were reported in the
10 years 2004–2013. Even with the high rates of vaccina-
tion coverage (95% coverage of both first and second dose)
over these 10 years, outbreaks would have been expected
within the age cohorts with large amounts of suscepti-
bility. To our knowledge, there were no supplementary
immunisation activities that could explain the absence of
outbreaks. It would be of value to determine whether the
country is now at high risk of large outbreaks in spite
of having previously interrupted transmission, or whether
there were issues with the serological tests conducted at
the time.
Israel and Spain, on the other hand, experienced large
numbers in spite of high levels of contact-adjusted immu-
nity. Three potential causes for this discrepancy suggest
themselves: First, in Spain, the samples were collected in
1996 when there was an ongoing large measles outbreak
and may therefore not reflect population-level immunity
in the years following. Second, drops in vaccination cov-
erage as well as vaccination campaigns may have changed
the risk of outbreaks during the 10 years following the
serological studies, although we found nothing in the
publicly available national-level vaccination data to sug-
gest any significant changes. Both Spain and Israel con-
sistently reported 94% first-dose MMR coverage in the
years following the seroprevalence studies. Third, serol-
ogy based on residual and population-based samples may
not always be representative of relevant immunity levels.
In Spain, a disproportionate number of cases occurred in
young adults [11], but there was nothing in the serological
data to suggest that this might be expected. Moreover, if
those lacking immunity are preferentially in contact with
each other because they cluster socially or geographically,
outbreaks could occur in these groups; population-level
serology might not provide a good estimate of realised
immunity levels in outbreak settings. In Israel, outbreaks
occurred in orthodox religious communities with very low
vaccination coverage [52]. More generally, herd immunity
thresholds have been shown to increase if non-vaccination
is clustered [53].
These examples highlight that taking into account het-
erogeneity is crucial. Our method can be applied to
lower levels than countries, such as municipalities or
counties. Further sub-national serological and epidemi-
ological studies, particularly in low-income countries at
high risk of measles outbreaks, could generate key insights
on the relationship between immunity levels, heterogene-
ity of susceptibility and outbreak risk [54, 55]. At the same
time, further studies of contact patterns across settings,
combined with models of such patterns where no data
have been collected, will make it possible to expand our
results to other countries and regions [56].
Conclusions
We have shown that combining national measles sero-
prevalence studies with data on contact patterns increases
their utility in predicting the expected case load and in
assessing how close a country is to eliminating measles.
Comparing past seroprevalence levels to the case load
in the following decade enabled us to establish a thresh-
old level of 93% contact-adjusted immunity that appeared
sufficient to ensure elimination. Translating this into tar-
get age-specific immunity levels that would be necessary
to achieve this level of immunity, we found that greater
immunity in 5–9-year-olds is needed than was previ-
ously recommended. While such high levels can be dif-
ficult to achieve, school entry provides an opportunity
to ensure sufficient vaccination coverage. Combined with
observations of contact patterns, further national and sub-
national serological studies could serve to highlight key
gaps in immunity that need to be filled in order to achieve
national and regional measles elimination.
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